<?xml version='1.0' encoding='utf-8'?>
<document id="29427485"><sentence text="Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in &quot;special populations&quot;." /><sentence text="The recommended combination of pangenotypic direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) associates the co-formulation of 2 or 3 second-generation DAAs" /><sentence text=" In the so-called &quot;special populations&quot; defined as patients with chronic kidney disease (CKD), HCV/HIV co-infection, HCV/HBV co-infection and an unsuccessful previous DAA regimen, these combinations have a high antiviral potency (sustained virologic response (SVR) &gt; 95%), fair tolerance and a reduced pill burden" /><sentence text="" /><sentence text="We have taken into account the scientific evidence on the treatment of &quot;special populations&quot;, in particular from the RUBY 1-2 trials, EXPEDITION 2-4 study, C-WORTHY trial, ASTRAL 5, POLARIS 1-4 studies, MAGELLAN 1 and REVENGE study" /><sentence text="" /><sentence text="CKD and HCV/HIV co-infection are not predictors of a non-viral response" /><sentence text=" The glecaprevir/pibentrasvir (Maviret) combination appears to be the first-line therapy for CKD patients while the sofosbuvir/vlpatasvir/voxaliprevir (Sovesi) combination is the first-line option for DAAs failures"><entity charOffset="116-126" id="DDI-PubMed.29427485.s8.e0" text="sofosbuvir" /><entity charOffset="127-137" id="DDI-PubMed.29427485.s8.e1" text="vlpatasvir" /><entity charOffset="138-150" id="DDI-PubMed.29427485.s8.e2" text="voxaliprevir" /><pair ddi="false" e1="DDI-PubMed.29427485.s8.e0" e2="DDI-PubMed.29427485.s8.e0" /><pair ddi="false" e1="DDI-PubMed.29427485.s8.e0" e2="DDI-PubMed.29427485.s8.e1" /><pair ddi="false" e1="DDI-PubMed.29427485.s8.e0" e2="DDI-PubMed.29427485.s8.e2" /><pair ddi="false" e1="DDI-PubMed.29427485.s8.e1" e2="DDI-PubMed.29427485.s8.e1" /><pair ddi="false" e1="DDI-PubMed.29427485.s8.e1" e2="DDI-PubMed.29427485.s8.e2" /></sentence><sentence text=" Both are effective in patients with HIV-or HBV-HCV co-infection and should be chosen according to the potential drug-drug interaction profile" /><sentence text="" /><sentence text="The notion of &quot;special populations&quot; is no longer pertinent with pangenotypic DAAs combinations" /><sentence text=" International guidelines recommend treating all infected patients and the next challenge is not the therapeutic choice, but to improve the limitations for screening and access to care in HCV infection" /><sentence text="" /></document>